NCT05816473 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Laine L, Jensen DM
Management of patients with ulcer bleeding. Am J Gastroenterol. 2012 Mar;107(3):345-60; quiz 361. doi: 10.1038/ajg.2011.480. Epub 2012 Feb 7.
Laine L
Risk Assessment Tools for Gastrointestinal Bleeding. Clin Gastroenterol Hepatol. 2016 Nov;14(11):1571-1573. doi: 10.1016/j.cgh.2016.08.003. Epub 2016 Aug 10. No abstract available.
Leonardi, P
M. 2009. Why do people reject new technologies and stymie organizational changes of which they are in favor? Exploring misalignments between social interactions and materiality. Human Communication Research, 35(3): 407-441.
Venkatesh, V
, Morris, M. G., Davis, G. B., & Davis, F. D. (2003). User Acceptance of Information Technology: Toward a Unified View. MIS Quarterly, 27(3), 425-478

Artificial Intelligent Clinical Decision Support System Simulation Center Study: Trust and Usefulness of Machine Learning Risk Stratification Tool for Acute Gastrointestinal Bleeding Using the Technology Acceptance Model

Details for clinical trial NCT05816473

Clinical trial NCT05816473 - References